Theravance Biopharma(Delisted) TBPH
$0.00 +$0.00 (0.00%)
Market closed · Oct 24, 12:40 am ET
Open$0.00
Prev close$0.00
Day range$0.00 – $0.00
Volume0.00
Market cap$884.18M
P/E (TTM)16.4
Dividend yield–
Earnings
Average move on report day±6.6%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+22.7%
Worst reaction-18.4%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2025/Q3 | 10 Nov 2025 | After Market | ±22.0% | +22.68% | Bigger than priced |
| 2025/Q2 | 12 Aug 2025 | After Market | ±14.1% | +4.19% | Within range |
| 2025/Q1 | 8 May 2025 | After Market | ±9.5% | -9.29% | Within range |
| 2024/Q4 | 26 Feb 2025 | After Market | ±22.1% | +2.09% | Within range |
| 2024/Q3 | 12 Nov 2024 | After Market | ±13.8% | +8.64% | Within range |
| 2024/Q2 | 5 Aug 2024 | After Market | ±12.3% | -18.35% | Bigger than priced |
| 2024/Q1 | 13 May 2024 | After Market | ±7.8% | -1.98% | Within range |
| 2023/Q4 | 26 Feb 2024 | After Market | ±17.6% | +4.98% | Within range |
| 2023/Q3 | 7 Nov 2023 | After Market | ±6.7% | +5.34% | Within range |
| 2023/Q2 | 7 Aug 2023 | After Market | ±9.7% | -0.92% | Within range |
| 2023/Q1 | 8 May 2023 | After Market | ±13.7% | +0.44% | Within range |
| 2022/Q4 | 27 Feb 2023 | After Market | ±19.6% | +2.27% | Within range |
| 2022/Q3 | 7 Nov 2022 | After Market | ±6.5% | +3.08% | Within range |
| 2022/Q2 | 4 Aug 2022 | After Market | ±16.6% | -7.81% | Within range |
| 2022/Q1 | 5 May 2022 | None | ±15.4% | -4.21% | Within range |
| 2021/Q4 | 23 Feb 2022 | None | ±29.6% | +9.00% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$20.73M-20.9% YoY
Operating profit$1.84M+167.6% YoY
Net profit-$5.90M-110.8% YoY
Diluted EPS-$0.11-110.2% YoY
Free cash flow-$6.97M-103.3% YoY
Operating cash flow-$6.97M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Operating margin9.2%
Net margin51.6%
Return on equity20.9%
Return on assets12.0%
Return on invested capital14.0%
Current ratio13.54
Liabilities / assets38.3%
Cash & investments$387.66M
Total debt$27.77M
Net cash (debt)$359.88M
Free cash flow / sales51.5%
No comments yet — be the first to weigh in on TBPH.
Sign in to join the discussion.